Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
FEDERAL TRADE COMMISSION v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Case Number:
1:09-mc-00564
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
December 09, 2016
FTC Says Boehringer Should Cough Up Pay-For-Delay Docs
The U.S. Federal Trade Commission asked a D.C. federal court Friday not to allow Boehringer Ingelheim Pharmaceuticals to delay producing documents related to a pay-for-delay suit over stroke prevention drug Aggrenox while the company appeals a decision on whether the documents are protected.
-
September 28, 2016
Boehringer Can Hide Emails In FTC Pay-For-Delay Suit
A D.C. federal judge found Tuesday that Boehringer Ingelheim Pharmaceuticals is protected by attorney-client privilege from disclosing the majority of subpoenaed financial documents in the Federal Trade Commission's pay-for-delay suit over stroke prevention drug Aggrenox.
-
September 27, 2012
Boehringer Can Keep Many Docs On Barr Deal Away From FTC
A Washington federal judge ruled Thursday that many of the documents the Federal Trade Commission had sought from Boehringer Ingelheim Pharmaceuticals Inc. about its patent settlements with Barr Pharmaceuticals Inc. were privileged but ordered the drugmaker to quickly turn over the rest.
-
December 09, 2011
FTC, Boehringer Wrangle Over Generics Settlement Docs
The Federal Trade Commission, on the hunt for documents relating to a patent settlement it is investigating between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drugs, told a judge Friday that the documents contained factual material, not just attorneys' mental impressions.
-
October 27, 2009
FTC Accuses Boehringer Of Subpoena Delay Tactics
The Federal Trade Commission, investigating a patent settlement between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drug entry, has asked for a court order requiring Boehringer to comply with the terms of a subpoena.